

Inna Viktorova

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1786331/inna-viktorova-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9 papers	1,686 citations	6 h-index	16 g-index
16 ext. papers	2,320 ext. citations	8.5 avg, IF	3.74 L-index

#	Paper	IF	Citations
9	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019 , 394, 1169-1180	40	106
8	Physicians guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019 , 21, 921-929	12.3	53
7	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2019 , 7, 618-628	18.1	120
6	The ESSE-RF2 epidemiological study in the Omsk Region: organization issues and the population response. <i>Profilakticheskaya Meditsina</i> , 2019 , 22, 85	0.5	3
5	Prevalence, Awareness, Treatment and Control of Hypertension in Russian Federation (Data of Observational ESSERF-2 Study). <i>Rational Pharmacotherapy in Cardiology</i> , 2019 , 15, 450-466	0.5	52
4	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018 , 379, 2097-2107	59.2	1277
3	Joint hypermobility in association with osteoarthritis: A familial case. <i>Profilakticheskaya Meditsina</i> , 2017 , 20, 42	0.5	
2	NON-ADHERENT BEHAVIOR IN PATIENTS WITH ANXIETY AND HYPERTENSION: FOCUS ON NON-PHARMACOLOGICAL TREATMENT AS A METHOD TO INCREASE COMPLIANCE. <i>Rational Pharmacotherapy in Cardiology</i> , 2016 , 12, 661-668	0.5	
1	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015 , 169, 631-638.e7	4.9	72